Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanley Cohen

Showing results (41-50 of 116) with videos related to

Pageof 12
Sort By:
Clinical Rheumatology|September 23, 2020
Correction to: Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritisGerd Burmester, Edit Drescher, Pawel Hrycaj, et al.
British Journal of Clinical Pharmacology|March 18, 2010
Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustmentStanley Cohen, Samuel H Zwillich, Vincent Chow, et al.
Academic Pathology|October 27, 2018
What Advice Current Pathology Chairs Seek From Former ChairsDavid N Bailey, Stanley Cohen, Avrum Gotlieb, et al.
Future Oncology (London, England)|November 14, 2019
Scientific rationale underpinning the development of biosimilar rituximab in hematological cancers and inflammatory diseasesWojciech Jurczak, Stanley Cohen, Timothy M Illidge, et al.
Clinical Rheumatology|September 3, 2020
Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritisGerd Burmester, Edit Drescher, Pawel Hrycaj, et al.
Clinical Pharmacology in Drug Development|July 7, 2020
A Randomized, Double-Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid ArthritisGerd Burmester, David Chien, Vincent Chow, et al.
Analytical Cellular Pathology (Amsterdam)|November 3, 2011
Localization of ORC1 during the cell cycle in human leukemia cellsFrederick D Coffman, Mai-Ling Reyes, Monique Brown, et al.
Arthritis and Rheumatism|March 29, 2002
A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis siccaDianne Petrone, John J Condemi, Rose Fife, et al.
Audiology & Neuro-Otology|October 29, 2010
A pilot study of rituximab in immune-mediated inner ear diseaseStanley Cohen, Peter Roland, Angela Shoup, et al.
Clinical Therapeutics|April 27, 2016
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic LupusStanley Cohen, Megan Clowse, Patricia Pardo, et al.
Pageof 12

Showing results (41-50 of 116) with videos related to

Sort By:
Pageof 12
Clinical Rheumatology|September 23, 2020
Correction to: Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritisGerd Burmester, Edit Drescher, Pawel Hrycaj, et al.
British Journal of Clinical Pharmacology|March 18, 2010
Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustmentStanley Cohen, Samuel H Zwillich, Vincent Chow, et al.
Academic Pathology|October 27, 2018
What Advice Current Pathology Chairs Seek From Former ChairsDavid N Bailey, Stanley Cohen, Avrum Gotlieb, et al.
Future Oncology (London, England)|November 14, 2019
Scientific rationale underpinning the development of biosimilar rituximab in hematological cancers and inflammatory diseasesWojciech Jurczak, Stanley Cohen, Timothy M Illidge, et al.
Clinical Rheumatology|September 3, 2020
Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritisGerd Burmester, Edit Drescher, Pawel Hrycaj, et al.
Clinical Pharmacology in Drug Development|July 7, 2020
A Randomized, Double-Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid ArthritisGerd Burmester, David Chien, Vincent Chow, et al.
Analytical Cellular Pathology (Amsterdam)|November 3, 2011
Localization of ORC1 during the cell cycle in human leukemia cellsFrederick D Coffman, Mai-Ling Reyes, Monique Brown, et al.
Arthritis and Rheumatism|March 29, 2002
A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis siccaDianne Petrone, John J Condemi, Rose Fife, et al.
Audiology & Neuro-Otology|October 29, 2010
A pilot study of rituximab in immune-mediated inner ear diseaseStanley Cohen, Peter Roland, Angela Shoup, et al.
Clinical Therapeutics|April 27, 2016
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic LupusStanley Cohen, Megan Clowse, Patricia Pardo, et al.
Pageof 12